GVK group chalks out an ambitious plan to retire debt in the holding companies of its core infrastructure business.

Aragen is a privately held US-based, pre-clinical CRO specializing in high-value biologics services. As per the deal, GVK Bio will acquire the capital stock of Aragen Bioscience.

The GVK Group employs many professionals, but G.V.K. Reddy always has the last word.

John W. Ellingboe has moved from representing a client of GVK Biosciences to working with them.

Two years after it slammed into a US regulatory wall, Ranbaxy Laboratories, under its Japanese owners, is working the hard way to be back among the stars.

BT asks the who’s who of India’s corporate world—as well as some professionals and leaders from other fields for good measure—to jog their memory and recall the best advice they ever got. What the advice was, who gave it to them and when, and how it helped them.

Call it the six-year-itch. Set up in 2002 by GVK scion G.V. Sanjay Reddy, GVK Biosciences is now talking leadership and on ways to get there quickly.

By selling out to Daiichi Sankyo, the CEO& MD of Ranbaxy hasn’t just netted a Rs 9,576-crore windfall, but brightened the company's future sans him in the global generics' marketplace. A report by Business Today's Shalini S. Dagar. Ranbaxy will continue acquisition, says CEORanbaxy to sell stake to Japan's Daiichi

India is critical to our future, says Robert R Ruffolo, 57, President, Wyeth Research & Development. That may sound like just another feel-good sound byte from a visiting foreign honcho, but Ruffolo and Wyeth have good reasons for banking on India.

Biotechnology jobs are on the rise.